January 2017

The latest from Cogstate, leaders in optimizing the measurement of cognition

Cogstate Announces Appointment of Jane McAloon to Board of Directors

January 30, 2017

Cogstate Ltd (ASX.CGS) is pleased to announce the appointment of Jane McAloonas an Independent Non-Executive Director and, following release of the Appendix 4D Half Year Financial Report on 23 February 2017, Chair of the Audit & Compliance Committee of Cogstate Ltd. Until mid-2015, Jane was part of the Group Management Committee of BHP Billiton as […]

Cogstate Announces Appointment of Dr. Richard Mohs to Board of Directors

January 24, 2017

Cogstate Ltd (ASX.CGS) is pleased to announce the appointment of Dr. Richard Mohs as a non-executive director. Dr. Mohs retired from Eli Lilly in 2015, where he held several leadership positions including Vice President for Neuroscience Early Clinical Development and Leader of the Global Alzheimer’s Drug Development Team. Before joining Eli Lilly in 2002, Richard […]

Cognitive Decline and PTSD Symptoms Linked In Large Study Of Civilian Women

January 20, 2017

Living through a traumatic event is an unfortunate reality for many people with each episode resulting in varying recovery timelines and potentially long-term effects. When lasting effects result in daily challenges to normal activities, a diagnosis of post-traumatic stress disorder (PTSD) can trigger a treatment protocol of medications, counseling and support to help manage ongoing […]